著者名,論文名,雑誌名,ISSN,出版者名,出版日付,巻,号,ページ,URL,URL(DOI)
Noboru Yamamoto and Takashi Seto and Makoto Nishio and Koichi Goto and Isamu Okamoto and Takeharu Yamanaka and Misa Tanaka and Koji Takahashi and Masahiro Fukuoka and Nobuyuki Yamamoto,Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567.,Journal of Clinical Oncology,0732-183X,American Society of Clinical Oncology (ASCO),2018-05-20,36,15_suppl,9007-9007,https://cir.nii.ac.jp/crid/1362262945979600512,https://doi.org/10.1200/jco.2018.36.15_suppl.9007